To evaluate long-term real-life results of dasatinib therapy among chronic phase chronic myeloid leukemia patients resistant or intolerant to imatinib, we retrospectively analyzed data of 118 patients treated in centers participating in the database INFINITY. With median follow-up of 37 months, estimated 5-year cumulative incidences of complete cytogenetic and major molecular responses were 78% and 68%, respectively. The estimated 5-year probability of overall survival (OS) and event-free survival (EFS) were 86% and 83%, respectively. Both OS and EFS were significantly improved among patients with BCR-ABL1 transcript level ≤10% at 3 months. Dasatinib toxicity was tolerable however persistent in almost half our patients, even after years of therapy. Pleural effusion occurred in 29% of patients and was responsible for 30% of dasatinib discontinuations. Our results confirmed very good efficacy and acceptable toxicity of dasatinib in second line setting and support the evidence and importance of high-quality real-life CML patient management.

4th Department of Internal Medicine Hematology University Hospital Hradec Kralove Hradec Kralove Czech Republic

Central European Institute of Technology Brno Czech Republic

Department of Hematooncology University Hospital Ostrava Ostrava Czech Republic

Department of Internal Medicine Hematology and Oncology University Hospital Brno and Masaryk University Brno Czech Republic

Institute of Biostatistics and Analyses Ltd Brno Czech Republic

Institute of Hematology and Blood Transfusion Praha Czech Republic

000      

00000naa a2200000 a 4500

001      

bmc21019574

003      

CZ-PrNML

005      

20210830101152.0

007      

ta

008      

210728s2021 xxu f 000 0|eng||

009      

AR

024    7_

$a 10.1080/10428194.2020.1827242 $2 doi

035    __

$a (PubMed)33021423

040    __

$a ABA008 $b cze $d ABA008 $e AACR2

041    0_

$a eng

044    __

$a xxu

100    1_

$a Zackova, Daniela $u Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Masaryk University, Brno, Czech Republic

245    10

$a Dasatinib treatment long-term results among imatinib-resistant/intolerant patients with chronic phase chronic myeloid leukemia are favorable in daily clinical practice / $c D. Zackova, H. Klamova, P. Belohlavkova, L. Stejskal, T. Necasova, L. Semerad, B. Weinbergerova, D. Srbova, J. Voglova, P. Cicatkova, Z. Sustkova, T. Hornak, J. Baranova, J. Prochazkova, J. Mayer

520    9_

$a To evaluate long-term real-life results of dasatinib therapy among chronic phase chronic myeloid leukemia patients resistant or intolerant to imatinib, we retrospectively analyzed data of 118 patients treated in centers participating in the database INFINITY. With median follow-up of 37 months, estimated 5-year cumulative incidences of complete cytogenetic and major molecular responses were 78% and 68%, respectively. The estimated 5-year probability of overall survival (OS) and event-free survival (EFS) were 86% and 83%, respectively. Both OS and EFS were significantly improved among patients with BCR-ABL1 transcript level ≤10% at 3 months. Dasatinib toxicity was tolerable however persistent in almost half our patients, even after years of therapy. Pleural effusion occurred in 29% of patients and was responsible for 30% of dasatinib discontinuations. Our results confirmed very good efficacy and acceptable toxicity of dasatinib in second line setting and support the evidence and importance of high-quality real-life CML patient management.

650    _2

$a dasatinib $x škodlivé účinky $7 D000069439

650    _2

$a lidé $7 D006801

650    _2

$a imatinib mesylát $x škodlivé účinky $7 D000068877

650    12

$a chronická myeloidní leukemie $x farmakoterapie $x genetika $7 D015464

650    12

$a chronická fáze myeloidní leukemie $x farmakoterapie $x genetika $7 D015466

650    _2

$a inhibitory proteinkinas $x škodlivé účinky $7 D047428

650    _2

$a retrospektivní studie $7 D012189

650    _2

$a výsledek terapie $7 D016896

655    _2

$a časopisecké články $7 D016428

655    _2

$a práce podpořená grantem $7 D013485

700    1_

$a Klamova, Hana $u Institute of Hematology and Blood Transfusion, Praha, Czech Republic

700    1_

$a Belohlavkova, Petra $u 4th Department of Internal Medicine - Hematology, University Hospital Hradec Kralove, Hradec Kralove, Czech Republic

700    1_

$a Stejskal, Lukas $u Department of Hematooncology, University Hospital Ostrava, Ostrava, Czech Republic

700    1_

$a Necasova, Tereza $u Institute of Biostatistics and Analyses, Ltd., Brno, Czech Republic

700    1_

$a Semerad, Lukas $u Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Masaryk University, Brno, Czech Republic

700    1_

$a Weinbergerova, Barbora $u Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Masaryk University, Brno, Czech Republic

700    1_

$a Srbova, Dana $u Institute of Hematology and Blood Transfusion, Praha, Czech Republic

700    1_

$a Voglova, Jaroslava $u 4th Department of Internal Medicine - Hematology, University Hospital Hradec Kralove, Hradec Kralove, Czech Republic

700    1_

$a Cicatkova, Petra $u Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Masaryk University, Brno, Czech Republic

700    1_

$a Sustkova, Zuzana $u Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Masaryk University, Brno, Czech Republic

700    1_

$a Hornak, Tomas $u Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Masaryk University, Brno, Czech Republic

700    1_

$a Baranova, Jana $u Institute of Biostatistics and Analyses, Ltd., Brno, Czech Republic

700    1_

$a Prochazkova, Jirina $u Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Masaryk University, Brno, Czech Republic

700    1_

$a Mayer, Jiri $u Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Masaryk University, Brno, Czech Republic $u Central European Institute of Technology, Brno, Czech Republic

773    0_

$w MED00003140 $t Leukemia & lymphoma $x 1029-2403 $g Roč. 62, č. 1 (2021), s. 194-202

856    41

$u https://pubmed.ncbi.nlm.nih.gov/33021423 $y Pubmed

910    __

$a ABA008 $b sig $c sign $y p $z 0

990    __

$a 20210728 $b ABA008

991    __

$a 20210830101152 $b ABA008

999    __

$a ok $b bmc $g 1690415 $s 1140020

BAS    __

$a 3

BAS    __

$a PreBMC

BMC    __

$a 2021 $b 62 $c 1 $d 194-202 $e 20201006 $i 1029-2403 $m Leukemia & lymphoma $n Leuk Lymphoma $x MED00003140

LZP    __

$a Pubmed-20210728